What is the standard usage and frequency of taking Romiplostim?

Romiplostim (Romiplostim) is a thrombopoietin receptor agonist (TPO-RA), used to treat chronic immune thrombocytopenia (ITP) and other diseases. It stimulates megakaryocytes in the bone marrow to produce more platelets by simulating the effects of natural thrombopoietin (TPO) in the body, thereby increasing peripheral platelet counts. Romiplostim is indicated for adults or children with ITP who have had an inadequate response to glucocorticoids, immunoglobulins, or splenectomy.

In terms of standardized use, romiplostim is not an oral drug but is administered by subcutaneous injection. The recommended starting dose is usually 11 microgram per kilogram of body weight (μg) once weekly, with individual dose adjustment based on the patient's platelet count. In order to maintain the platelet count within a safe range (generally ≥50×10⁹/L but not higher than the upper limit of normal), the doctor will adjust the dose every week based on platelet changes, and the maximum dose should not exceed 10micrograms/kg per week.

During the treatment process, patients need to draw blood regularly every week to monitor the number of platelets, and adjust the dosage under the guidance of a doctor. The efficacy of romiplostim usually begins to appear after 1 to 2 weeks, and some patients may experience an increase in platelets within the first week. If the platelet count does not improve within 4 weeks, the doctor may reassess whether to continue treatment or adjust to other platelet-raising drugs.

It should be emphasized that romiplostim is a maintenance treatment drug and cannot be stopped or the frequency of dosing changed on its own. Sudden discontinuation may cause a sharp drop in platelets and increase the risk of bleeding, so any adjustments should be made at the discretion of your doctor. In addition, this drug should be used in experienced medical institutions and injected by professionals to ensure safe administration. In summary, romiplostim needs to be injected subcutaneously at a frequency of once a week and the dose adjusted based on platelet count to achieve safe and effective long-term control.

Reference: https://en.wikipedia.org/wiki/Romiplostim